Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.
作者信息
Costa Luciano J, Medvedova Eva, Dhakal Binod, Dholaria Bhagirathbhai R, Godby Kelly N, Bal Susan, Ravi Gayathri, Giri Smith, Chhabra Saurabh, Silbermann Rebecca, Callander Natalie S
机构信息
Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Division of Hematology/Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
出版信息
Blood Cancer J. 2025 Feb 5;15(1):13. doi: 10.1038/s41408-025-01219-7.
Abstract
摘要
相似文献
1
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.
Blood Cancer J. 2025 Feb 5;15(1):13. doi: 10.1038/s41408-025-01219-7.
2
Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.
Ther Adv Hematol. 2021 Sep 30;12:20406207211030369. doi: 10.1177/20406207211030369. eCollection 2021.
3
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol. 2022 Sep;97(9):1170-1177. doi: 10.1002/ajh.26640. Epub 2022 Jul 6.
4
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
5
Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis.
Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171.
6
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424.
7
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Blood Adv. 2024 Dec 10;8(23):5993-6002. doi: 10.1182/bloodadvances.2024014139.
8
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Transplant Cell Ther. 2022 Nov;28(11):760.e1-760.e5. doi: 10.1016/j.jtct.2022.07.030. Epub 2022 Aug 5.
9
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Clin Hematol Int. 2025 Apr 11;7(2):1-19. doi: 10.46989/001c.133682. eCollection 2025.
10
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025.
引用本文的文献
1
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences.
Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025027. doi: 10.4084/MJHID.2025.027. eCollection 2025.
本文引用的文献
1
MRD accelerating myeloma drug development.
Blood. 2024 Jul 25;144(4):345-347. doi: 10.1182/blood.2024025421.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
3
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.
Blood. 2024 Jul 25;144(4):359-367. doi: 10.1182/blood.2024024371.
4
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
5
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.
6
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083.
7
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
8
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
9
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
BMC Cancer. 2020 Jun 30;20(1):612. doi: 10.1186/s12885-020-07077-9.
10
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
Zotero 插件